Skip to search formSkip to main contentSkip to account menu

JNJ-37822681

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Dual time-point imaging for post-dose binding potential estimation applied to a [11C]raclopride PET dose occupancy study
Receptor occupancy studies performed with PET often require time-consuming dynamic imaging for baseline and post-dose scans… 
2014
2014
Differential responses to JNJ‐37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague–Dawley rat general toxicology studies: clinical observations…
JNJ‐37822681 is a potent, specific and fast dissociating dopamine D2 receptor antagonist intended for the treatment of… 
2013
2013
Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia.
BACKGROUND The highly selective and fast dissociating D2 receptor antagonist JNJ-37822681 may be associated with lower risk for… 
2012
2012
Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681
Using the rate of dissociation from the D2 receptor as a means to screen novel compounds for antipsychotic drug candidates, the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)